APL2
PreclinicalSmall molecule
Apellis PharmaceuticalsAPL2 is one of 44 small molecule programs targeting Focal Segmental Glomerulosclerosis. It is currently in Preclinical.
2
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
51 competitors in Focal Segmental Glomerulosclerosis
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glucophage
EMD SeronoApproved
Empaveli
Apellis PharmaceuticalsApproved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Rituxan
RochePhase 3
Avapro
SanofiPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Cyclosporin
AstraZenecaPhase 3
Cellcept
RochePhase 2
Simulect
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for APL2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company